Pulmatrix, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated November 29, 2018, details a material definitive agreement entered into by Pulmatrix, Inc. (the "Company"). The Company, a Delaware corporation, executed a Securities Purchase Agreement with an institutional investor to raise capital through a registered direct offering and a concurrent private placement.
Key Financial Metrics and Transaction Details
The filing outlines a capital raise structured as follows:
- Common Stock Sale: 2,400,000 shares sold at $0.32 per share, generating gross proceeds of $768,000.
- Pre-Funded Warrants: 6,975,000 pre-funded warrants sold at $0.31 per share, generating gross proceeds of $2,162,250. These were issued to prevent the purchaser from exceeding a 4.99% beneficial ownership limit.
- Total Gross Proceeds: $2,930,250 (before deduction of offering expenses).
- Common Warrants: Issued in a concurrent private placement, these warrants allow the purchase of 9,375,000 shares at an exercise price of $0.39 per share. They are exercisable six months after issuance and terminate five and one-half years after issuance.
The filing does not provide specific data on the Company's historical revenue, profit, cash flow, margins, or existing debt levels.
Material Changes and Transaction Structure
The primary material change is the dilution of existing shareholders due to the issuance of new equity and warrants. The transaction structure includes specific beneficial ownership limitations:
- Holders cannot exercise warrants if it would result in beneficial ownership exceeding 4.99% of outstanding shares.
- Holders may increase this limit to 9.99% upon providing 61 days' prior notice.
- The closing of the transaction is expected to occur on or around December 3, 2018, subject to customary closing conditions.
Outlook, Risks, and Contingencies
Registration Obligations: The Company is obligated to file a registration statement on Form S-1 within 120 calendar days of the issuance of the Common Warrants to facilitate their resale. The Company must use best efforts to declare this statement effective and maintain its effectiveness until the warrants are sold or terminate.
Risks and Disclaimers: The representations and warranties in the Purchase Agreement are for the benefit of the parties to the agreement and do not constitute statements of fact for investors. Information regarding the Company's condition may change after the agreement date. The press release associated with this filing is not deemed "filed" under the Exchange Act.
Key Facts for Investor Verification
- Verify the actual closing date and confirmation of the $2,930,250 gross proceeds.
- Monitor the filing of the Form S-1 registration statement for the Common Warrants within the required 120-day window.
- Assess the impact of the 9,375,000 potential new shares from Common Warrants on future dilution.
- Review the Company's cash position post-closing to determine runway for operations, as historical financials are not included in this filing.